Supported telemonitoring improved HbA1c and blood pressure in type 2 diabetes

• Adjusted mean HbA1c was 5.60 mmol/mol lower in the telemonitoring group at 9 months.
• Ambulatory systolic and diastolic blood pressure were both lower with telemonitoring than with usual care.
• Weight, prescribing patterns, and most health service use measures were not clearly different between groups.

These findings apply most directly to adults with type 2 diabetes in primary care who have poor glycemic control, can use home monitoring equipment, and have access to remote clinician follow-up. The results are especially relevant to UK-style family practice settings, but may also inform similar telehealth programs elsewhere.

This was a structured telemonitoring program, not simple unsupported self-monitoring. Participants transmitted readings, and clinicians reviewed results regularly and contacted patients when needed. The benefits may depend on that support model, patient engagement, and the local health system’s ability to respond to incoming data. It is also not yet clear whether the improvement lasts after monitoring stops.

• Participants and clinicians could not be fully blinded to group assignment.
• Only a minority of invited eligible patients joined the trial, so participants may not represent all patients with poorly controlled diabetes.
• The study did not show how long the benefit lasts after the 9-month intervention ends.
• The exact mechanism of benefit was unclear because medication changes and self-management behavior may both have contributed.